Amarin Corp Plc (AMRN)

[Biobillionair]

Amarin was ask for an expensive outcomes study, It's called REDUCE-IT. It was designed under SPA also. The FDA may get a chance to review the current status of REDUCE-IT and probably the reason they wanted REDUCE-IT 50% enrolled before Anchor sNDA. Early data should point to success when reviewing the JELIS timing.
In fact, the FDA may have reviewed REDUCE-IT data prior to the acceptance of the sNDA for Anchor.